Mass Exodus

Discussion in 'Zogenix' started by Anonymous, Oct 9, 2014 at 2:06 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Product launched 7 mos ago: Senior Leadership leaving and being pushed out (Scott and Nelson), Short term mindset of Rich and Roger, managers and reps let go for performance during launch, constant evaluation of territories, lack of understanding from management on outside pressures not to use ZER., weak managed care coverage, weak benefits and limited vacation time, stocks that are worthless, several competitor entries coming with better ran companies with track record in pain space, and finally the uncertainty of Zogenix and all of our futures- So were recent resignations a sign of what is to come or when will the Mass Exodus begin??
     

  2. Anonymous

    Anonymous Guest

    Get your facts straight--Nelson left because Zogenix no longer had a migraine product and his expertise is customer touchpoint for migraine prescribers, particularly headache specialists.
    As to the mass exodus, it is probably coming soon based on all of the above mentioned reasons. The heat has not even been turned on yet to the extent that it will in the next few days. And just wait until you see the Q4 Bonus plan. The exodus will follow.
     
  3. Anonymous

    Anonymous Guest

    PegLegMorgan needs to go ASAP!

    -KB
     
  4. Anonymous

    Anonymous Guest

    You need to buy another cat and stop obsessing over other women KB.
     
  5. Anonymous

    Anonymous Guest

    HQ has no clue. ZER Express? Like speciality offices don't have Cover My Meds on a Favorites button in their browser. ePocrates formulary lookup? All NC or ? Don't dare ask about contracting. Or what Regional Account Directors really do. Or Marketing people since the initial launch materials? Nothing new to brand the product. Or training? Like we need two trainers. Or two ABD's. Mgd markets don't have plan contacts or much less, visit them - we have vendors with the most inaccurate information I've ever seen purchased by any pharma company- and its sold by MM to HQ as the gospel. They have email addresses to plan secretaries. They have field sales ask MDs sign the back of office business cards just to secure a appointment because their initial requests have been denied - 9 months into launch no less- great plan! No coverage in 50% of mail order. No coverage in 50% of commercial and 100% PA in Med D plans. BTW...PA = no copay reduction or month 2 cost cost savings in a huge generic market. Hmm. It's no wonder we are chasing NRx every month. Who would be so foolish as to refill at $350+ per Rx when generic or Tier 2 Oxy is available for $20-40 MAX?

    Yes you dumbasses. Its the salesforce. The salesforce put this team of leadership .11 cents away from a NASDAQ delisting. Ok. All the while Roger and Steve issue 50K of common stock to themselves hoping someone will takeover their mess of a creation. Why do you think Zogenix was told NO on a co-promote? We aren't stable enough. But we are dumb enough organizationally to tell everyone about the possibility.

    They made those initial interviews an incredible misrepresentation of the truth.
    Im such a fool.

    And then there is the offer to call the VP on his cellphone is discuss any issues or challenges. Good lord.
     
  6. Anonymous

    Anonymous Guest

    I feel for you. But what leverage does Z have to gain any type of favorable contracting?
     
  7. Anonymous

    Anonymous Guest

    AMEN! Well said and sadly, ALL TRUE! Anyone planning to interview for or apply to one of our many vacancies posted should seriously take heed. The problem is not the sales force, the sales force of such TALENTED individuals they claimed they were initially so glad to hire; the problem is senior management-specifically the VP of Sales, who is so far removed from the truth of the ZER marketplace, that he doesn't even recognize silence on his conference calls as the sales force sending him a message. It can't be long before this company can no longer stay afloat.
     
  8. Anonymous

    Anonymous Guest

    price. they need to price this formulation to sell. payers will eat it up if they can take a pound of flesh out of Purdue's hide. they are just dying for the opportunity. how are you guys contracting this stuff?
     
  9. Anonymous

    Anonymous Guest

    Yeah right....payers are just waiting for Purdue's q24h hydrocodone to get approved and will contract for that. Good luck selling Zoshito ER (abuse deterrent properties or not) after that!
     
  10. Anonymous

    Anonymous Guest

    The manager in Denver has applied to Purdue. The rats are jumping off this sinking ship!
     
  11. Anonymous

    Anonymous Guest

    It's amazing the whining on this board, please all leave the company so we can move on. Most of you are Purdue reps anyway. I see your scum in every office I go to. Please quit and move on if all you can do is bitch.
     
  12. Anonymous

    Anonymous Guest

    What makes you think payers give a crap about Purdue's product? They don't. They just care about price. Zohydro can compete with Purdue
     
  13. Anonymous

    Anonymous Guest

    I don't where to start with your lack of pain/managed market knowledge. Purdue has strong pull with managed care companies/Pain Specialists etc. with multiple larger market share product lines (ie OxyContin=$2B etc) that have more of an effect on patient coverage access than dropping your pants to entice better coverage for ZER that is a drop in the ERO bucket. Like tommy boy said, "You can drop the rebate price, but it's still a guaranteed piece of Zoshito!"
     
  14. Anonymous

    Anonymous Guest

    That was true 5 years ago. Now it's not, and if you continue to think that way, you'll be El Shito Sales Repo. The old OC had a nice pop with the immediate release layer (patients saw it as a sign of efficacy). Patients loved, docs loved it, and payers had to reimburse it or face the ire of angry patients with no other good options. New market entrants had a real tough time, because Purdue would threaten loss of rebates on a high volume drug, which scared the piss out of payers. That world is gone. The new formulation is a big as a house, doesn't have the pop of the old OC, and is just an average pill. The customer loyalty to the new OC isn't there (or isn't strong) and the right strategy can cut Purdue down at the knees. Stop thinking like it's 2006. Give payers a great deal, set the reps loose on pain specialists, and pave the path for the abuse-deterrent formulation. Then make $400 million a year and move on to your next product before it's too late.
     
  15. Anonymous

    Anonymous Guest

    Ok Roger.
     
  16. Anonymous

    Anonymous Guest

    Contracting? LOL.
     
  17. Anonymous

    Anonymous Guest


    I take that to mean your contracting is a tad suboptimal?

    I'm no contracting expert, and it's risky for an idiot like me to have an opinion on this stuff, but it's a freaking ER opioid. It's not that complicated. Sell it cheap and I guarantee you payers will listen. Payers don't have any incentive anymore to stick with Purdue. The glory days for them are over.
     
  18. Anonymous

    Anonymous Guest

    You're right about that....Purdue isn't counting nearly as much on the business from addicts these days due to the OP version. You guys are going after it with ZER and can have it! I'm also looking forward to your argument with support that shows hydrocodone works as well or better than oxycodone (even a so called average version). I know you stopped working in 2006, but still collect a paycheck so might be a good idea to get out and talk to a pain specialist or two for the real story:)
     
  19. Anonymous

    Anonymous Guest


    So this is how you spend your Friday nights? Up all night posting on here fuckface? Really sad actually.
     
  20. Anonymous

    Anonymous Guest

    If you're saying opioids are dangerous and shouldn't be prescribed (or at least not prescribed unless the prescriber is proficient in risk assessment, treatment, and monitoring), then you'll get no argument from me. But as long as 30 mg of immediate-release oxycodone is still on the market, available generically, and sky rocketing in sales (because it's now the best source of oxycodone on the market), then all the crap about Zohydro being dangerous is bullshit. I'd rather have Zohydro, which is under a REMS and has extreme scrutiny, than Roxicodone on the market.